ATA 2016

The first-in-class compound CUDC-907, which is being tested for multiple myeloma and refractory lymphoma, may be promising for anaplastic thyroid cancer and poorly differentiated thyroid cancer.

Long-term recurrence rates appear to be low following the use of recombinant human thyrotropin for postoperative ablation in low-risk thyroid cancer.

Initiating treatment with the mTor inhibitor everolimus followed by the somatostatin analogue pasireotide may be beneficial in advanced thyroid cancer.

A new study has validated the American Thyroid Association sonographic pattern for selection of thyroid nodules undergoing ultrasound-guided fine needle aspiration.

Active surveillance in low-risk thyroid cancer may be better than immediate surgery in some patients.

Despite side effects, patients with differentiated thyroid cancer taking lenvatinib may experience better outcomes with close monitoring.